- Advanced search
- Immuno Portal
- Malaria Portal
rifamycin SV is an approved drug (FDA (2018))
Compound class: Natural product or derivative
Comment: One of the Ansamycin group of antibiotics. Rifamycin is a natural antibiotic that is produced by Streptomyces mediterranei that exhibits antibiotic and antitubercular properties. Rifamycins are particularly effective against mycobacteria, and are most commonly used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG et al.. (2014)
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.
J Travel Med, 21 (6): 369-76. [PMID:25345982]
2. Lin SW, Lin CJ, Yang JC. (2017)
Rifamycin SV MMX for the treatment of traveler's diarrhea.
Expert Opin Pharmacother, 18 (12): 1269-1277. [PMID:28697313]
3. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. (2002)
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
Hepatology, 36 (1): 164-72. [PMID:12085361]